Fu Zhenyue, Liu Pengfei, Gao Xiya, Shi Shuqing, Li Yumeng, Zhang Bingxuan, Wu Huaqin, Song Qingqiao
Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Department of General Internal Medicine, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Cardiovasc Med. 2024 Sep 30;11:1461073. doi: 10.3389/fcvm.2024.1461073. eCollection 2024.
To evaluate the association between systemic inflammatory markers and clinical outcomes (all-cause mortality, cardiovascular mortality, and rehospitalization) in patients with heart failure with preserved ejection fraction (HFpEF).
We conducted a comprehensive literature search in PubMed, Embase, and Ovid Medline databases from inception to June 27, 2024. Studies were included if they were observational clinical studies involving HFpEF patients over 18 years old, with exposure to systemic inflammatory markers and reporting on adverse prognosis outcomes. The Newcastle-Ottawa Scale (NOS) was used to assess study quality.
Eight studies ultimately included in the meta-analysis which involved 9,744 participants from six countries. The meta-analysis showed that systemic inflammatory markers were significantly associated with all-cause mortality (HR 1.43, 95% CI 1.19-1.72, < 0.05), cardiovascular mortality (HR 2.04, 95% CI 1.33-3.12, < 0.05), and cardiovascular rehospitalization (HR 2.83, 95% CI 0.92-8.67, < 0.05) in HFpEF patients. Low heterogeneity was observed across studies (I = 0.00%). Sensitivity and publication bias analyses indicated that the results were robust.
Systemic inflammatory markers demonstrate significant predictive value for adverse clinical outcomes in HFpEF patients. The findings suggest that monitoring systemic inflammation may provide valuable prognostic information for clinicians managing HFpEF patients.
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=562698, identifier (CRD42024562698).
评估射血分数保留的心力衰竭（HFpEF）患者全身炎症标志物与临床结局（全因死亡率、心血管死亡率和再住院率）之间的关联。
我们在PubMed、Embase和Ovid Medline数据库中进行了全面的文献检索，检索时间从数据库建立至2024年6月27日。纳入的研究需为观察性临床研究，涉及18岁以上的HFpEF患者，暴露于全身炎症标志物并报告不良预后结局。采用纽卡斯尔-渥太华量表（NOS）评估研究质量。
最终纳入荟萃分析的有8项研究，涉及来自6个国家的9744名参与者。荟萃分析表明，全身炎症标志物与HFpEF患者的全因死亡率（HR 1.43，95%CI 1.19 - 1.72，P < 0.05）、心血管死亡率（HR 2.04，95%CI 1.33 - 3.12，P < 0.05）和心血管再住院率（HR 2.83，95%CI 0.92 - 8.67，P < 0.05）显著相关。各研究间观察到低异质性（I² = 0.00%）。敏感性和发表偏倚分析表明结果可靠。
全身炎症标志物对HFpEF患者的不良临床结局具有显著预测价值。研究结果表明，监测全身炎症可能为管理HFpEF患者的临床医生提供有价值的预后信息。
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=562698，标识符（CRD42024562698）。
